Nanexa ABFRA:40M -2.89%53 Market Cap is €61.07 Mil as of Jun. 29, 2026. GuruFocus rates FRA:40M with a GF Score™ of 53/100 and a GF Value™ of €0.17 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,020 Drug Manufacturers companies, Nanexa AB ranks worse than 64.41% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Nanexa AB's share price for the quarter that ended in Mar. 2026 was €0.311. Nanexa AB's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 184.79 Mil. Therefore, Nanexa AB's market cap for the quarter that ended in Mar. 2026 was €57.47 Mil.
Nanexa AB's quarterly market cap
increased
from Sep. 2025 (€27.26 Mil) to Dec. 2025 (€69.99 Mil) but then
declined
from Dec. 2025 (€69.99 Mil) to Mar. 2026 (€57.47 Mil).
Nanexa AB's annual market cap
increased
from Dec. 2023 (€11.70 Mil) to Dec. 2024 (€23.41 Mil) and
increased
from Dec. 2024 (€23.41 Mil) to Dec. 2025 (€69.99 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Nanexa AB's Enterprise Value for Today is €54.56 Mil.
Nanexa AB (FRA:40M) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Nanexa AB Market Cap Related Terms
Nanexa AB Market Cap Historical Data
* Premium members only.
The historical data trend for Nanexa AB's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Nanexa AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanexa AB Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nanexa AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Nanexa AB's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Nanexa AB's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanexa AB (FRA:40M) has a Market Cap of €61.07 Mil as of Jun. 29, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Nanexa AB and its competitors. According to the industry distribution chart, Nanexa AB ranks #657 out of 1020 companies in the Drug Manufacturers industry, placing it in the top 64.4%.
Is Nanexa AB's Market Cap too high?
Nanexa AB's current Market Cap is €61.07 Mil. Based on the distribution chart, Nanexa AB ranks #657 out of 1020 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Nanexa AB has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nanexa AB's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Nanexa AB ranks #657 out of 1020 companies for Market Cap. This places Nanexa AB in the lower half of its industry. The industry median Market Cap is 206.61. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 206.61, based on 1,020 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Nanexa AB and its competitors. For the Drug Manufacturers industry, the median Market Cap is 206.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanexa AB's current Market Cap is €61.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanexa AB stock overvalued right now?
Based on GuruFocus' analysis, Nanexa AB (FRA:40M) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.17, compared to a current price of €0.30 — trading 77.9% above its estimated fair value. The current Market Cap is €61.07 Mil. Nanexa AB's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Nanexa AB (FRA:40M), the current Market Cap is €61.07 Mil as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanexa AB (FRA:40M) Overvalued in 2026?
Based on GuruFocus' analysis, Nanexa AB stock appears to be overvalued.
The current stock price of €0.30 is trading 77.9% above its estimated GF Value™ of €0.17.
GuruFocus considers Nanexa AB to be Significantly Overvalued.
Key valuation signals for FRA:40M:
Market Cap: €61.07 Mil
GF Value™: €0.17 vs. price of €0.30 (77.9% above fair value)
No single metric tells the full story. See the FRA:40M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanexa AB is a pharmaceutical company developing injectable drug products based on the proprietary drug delivery system PharmaShell - the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. The company develops its products and also has collaboration agreements with several pharma companies, among others AstraZeneca. Geographically, the company derives maximum revenue from Nordic countries, while it also has its presence in Europe (excluding the Nordic countries), North America, and Asia.
53GF Score
Get the complete analysis for FRA:40M
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:40M has been successfully added to your 
